inclusion

(redirected from inclusion body)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to inclusion body: inclusion body disease

inclusion

noun all acceptance, all-embracing uniierse, all-encompassing universe, all facets, blanket analysis, broad analysis, compendious amount, comprehensive number, diverse mix, diverse mixture, every facet, every side, exhaustive approach, extensive analysis, full vision, mainstreaming everyone, sweeping analysis, total number, total scope, umbrella, universe, unlimited acceptance
Associated concepts: inclusion of children with disabilities, inclusionary approach
See also: acceptance, accession, addendum, admittance, affiliation, appendix, composition, coverage, insertion, scope
References in periodicals archive ?
A56R, viral hemagglutinin; B19R, soluble alpha/beta interferon [IFN] receptor; E3L, dsRNA-binding protein; rpo 132-ATIp4c-A27L, a region that codes for the major protein of the A-type inclusion body (14); NA, not available.
The term hereditary inclusion body myopathy (h-IBM) was introduced in 1993 to designate a familial form of muscle disease similar pathologically to sporadic IBM (s-IBM), except for the lack of lymphocytic mononuclear cell inflammation.
Gene for A-type inclusion body protein is useful for a polymerase chain reaction assay to differentiate orthopoxviruses.
Summary of Bcl-2, Bcl-X, and Bax Immunoreactivity in Inclusion Body Myositis (N = 27) Degene- Regene- Subsar- rating rating Autophagic colemmal Antibody Inflammation Fibers Fibers Vacuoles Staining Bax 26 (96) * 24 (89) 24 (89) 24 (89) 21 (78) Bcl-2 27 (100) 2 (7) 21 (78) 2 (7) 6 (22) Bcl-x 8 (30) 3 (11) 4 (15) 3 (11) 1 (4) * Values are expressed as number positive (%).
The program is currently in a Phase I/II trial at Nationwide Children's Hospital in adult patients with Becker muscular dystrophy and inclusion body myositis, a trial funded by the foundation Parent Project Muscular Dystrophy.
a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration.
a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7 (MPS 7).
a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the Phase 1 study of UX001 for hereditary inclusion body myopathy (HIBM) has been completed.
Ultragenyx' lead program, UX001, is being evaluated as a potential treatment for GNE myopathy, also known as hereditary inclusion body myopathy (HIBM).
The Phase I/II trial, funded by a grant from Parent Project Muscular Dystrophy, is enrolling patients with Becker muscular dystrophy and inclusion body myositis.
will inject a modified virus (vector) carrying the gene for the muscle growth-stimulating protein follistatin into the quadriceps muscles of volunteers with Becker muscular dystrophy and sporadic inclusion body myositis.